A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
NCT ID: NCT05986292
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
10000 participants
INTERVENTIONAL
2020-01-30
2027-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain
NCT04529096
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain
NCT05086289
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain
NCT05630196
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
NCT07285018
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
NCT04476108
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Note: Results for all outcomes are posted in the intervention records. No need for duplication.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY3016859 Osteoarthritis ISA
Participants are randomized to receive either active LY3016859 or matching placebo
Placebo
Placebo administered IV
LY3016859 ISA
Administered intravenously (IV)
LY3016859 Diabetic Neuropathic Pain ISA
Participants are randomized to receive either active LY3016859 or matching placebo
Placebo
Placebo administered IV
LY3016859 ISA
Administered intravenously (IV)
LY3016859 Chronic Back Pain ISA
Participants are randomized to receive either active LY3016859 or matching placebo
Placebo
Placebo administered IV
LY3016859 ISA
Administered intravenously (IV)
LY3556050 Osteoarthritis ISA
Participants are randomized to receive either active LY3556050 or matching placebo
Placebo Oral
Placebo administered orally
LY3556050 ISA
Administered orally
LY3556050 Diabetic Neuropathic Pain ISA
Participants are randomized to receive either active LY3556050 or matching placebo
Placebo Oral
Placebo administered orally
LY3556050 ISA
Administered orally
LY3556050 Chronic Back Pain ISA
Participants are randomized to receive either active LY3556050 or matching placebo
Placebo Oral
Placebo administered orally
LY3556050 ISA
Administered orally
LY3526318 Osteoarthritis ISA
Participants are randomized to receive either active LY3526318 or matching placebo
Placebo Oral
Placebo administered orally
LY3526318 ISA
Administered orally
LY3526318 Diabetic Neuropathic Pain ISA
Participants are randomized to receive either active LY3526318 or matching placebo
Placebo Oral
Placebo administered orally
LY3526318 ISA
Administered orally
LY3526318 Chronic Back Pain ISA
Participants are randomized to receive either active LY3526318 or matching placebo
Placebo Oral
Placebo administered orally
LY3526318 ISA
Administered orally
LY3857210 Osteoarthritis ISA
Participants are randomized to receive either active LY3857210 or matching placebo
LY3857210 ISA
Administered orally
Placebo Oral
Placebo administered orally
LY3857210 Diabetic Neuropathic Pain ISA
Participants are randomized to receive either active LY3857210 or matching placebo
LY3857210 ISA
Administered orally
Placebo Oral
Placebo administered orally
LY3857210 Chronic Back Pain ISA
Participants are randomized to receive either active LY3857210 or matching placebo
LY3857210 ISA
Administered orally
Placebo Oral
Placebo administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY3857210 ISA
Administered orally
Placebo Oral
Placebo administered orally
Placebo
Placebo administered IV
LY3016859 ISA
Administered intravenously (IV)
LY3556050 ISA
Administered orally
LY3526318 ISA
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* have a history of daily pain for at least 12 weeks based on participant report or medical history
* have a value of ≤30 on the pain catastrophizing scale
* have a body mass index \<40 kilogram/square meter (kg/m²) (inclusive)
* are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.
* are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study
Exclusion Criteria
* have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)
* have surgery planned during the study for any reason, related or not to the disease state under evaluation.
* have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
* have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
* have fibromyalgia
* have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)
* have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.
* have a positive human immunodeficiency virus (HIV) test result at screening
* have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Research Associates
Birmingham, Alabama, United States
Simon Williamson Clinic
Birmingham, Alabama, United States
Synexus Clinical Research - Glendale
Glendale, Arizona, United States
Central Phoenix Medical Clinic
Phoenix, Arizona, United States
Arizona Research Center
Phoenix, Arizona, United States
Alliance for Multispecialty Research, LLC
Tempe, Arizona, United States
Irvine Clinical Research
Irvine, California, United States
Desert Oasis Healthcare Medical Group
Palm Springs, California, United States
Artemis Institute for Clinical Research
Riverside, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
CMR of Greater New Haven
Hamden, Connecticut, United States
VIN-Julie Schwartzbard
Aventura, Florida, United States
Bradenton Research Center, Inc.
Bradenton, Florida, United States
Clinical Research of South Florida
Coral Gables, Florida, United States
Accel Research Sites - DeLand Clinical Research Unit
DeLand, Florida, United States
K2 MEDICAL Research THE VILLAGES
Lady Lake, Florida, United States
K2 Medical Research ORLANDO
Maitland, Florida, United States
Merritt Island Medical Research, LLC
Merritt Island, Florida, United States
Flourish Research - Miami, LLC
Miami, Florida, United States
University of Miami Don Suffer Clinical Research Building
Miami, Florida, United States
New Horizon Research Center
Miami, Florida, United States
Suncoast Clinical Research, Inc.
New Port Richey, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Synexus Clinical Research US, Inc.
Orlando, Florida, United States
Synexus Clinical Research - St. Petersburg
Pinellas Park, Florida, United States
Martin E. Hale M.D., P.A.
Plantation, Florida, United States
Precision Clinical Research
Sunrise, Florida, United States
Charter Research - Lady Lake
The Villages, Florida, United States
Synexus Clinical Research US, Inc.
The Villages, Florida, United States
Conquest Research
Winter Park, Florida, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States
Synexus Clinical Research
Chicago, Illinois, United States
Northwestern University
Chicago, Illinois, United States
Cotton O'Neil Clinical Research Center - Central Office
Topeka, Kansas, United States
DelRicht Research
New Orleans, Louisiana, United States
Boston Clinical Trials
Boston, Massachusetts, United States
ActivMed Practices and Research
Methuen, Massachusetts, United States
Lucida Clinical Trials
New Bedford, Massachusetts, United States
MedVadis Research Corporation
Waltham, Massachusetts, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
StudyMetrix Research
City of Saint Peters, Missouri, United States
Clinvest Research LLC
Springfield, Missouri, United States
Synexus Clinical Research US, Inc.
Omaha, Nebraska, United States
Rochester Clinical Research, LLC
Rochester, New York, United States
PharmQuest
Greensboro, North Carolina, United States
Lillestol Research
Fargo, North Dakota, United States
Synexus - Cincinnati
Cincinnati, Ohio, United States
Aventiv Research Inc
Columbus, Ohio, United States
META Medical Research Institute
Dayton, Ohio, United States
DelRicht Research
Tulsa, Oklahoma, United States
Altoona Center For Clinical Research
Duncansville, Pennsylvania, United States
Clinical Research Center of Reading,LLC
Wyomissing, Pennsylvania, United States
Coastal Carolina Research Center
North Charleston, South Carolina, United States
FutureSearch Trials of Neurology
Austin, Texas, United States
Synexus
Dallas, Texas, United States
Cedar Health Research
Dallas, Texas, United States
Re:Cognition Health - Fort Worth
Fort Worth, Texas, United States
Synexus Clinical Research US, Inc.
San Antonio, Texas, United States
SYNEXUS
Murray, Utah, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Rainier Clinical Research Center
Renton, Washington, United States
Ponce Medical School Foundation Inc.
Ponce, , Puerto Rico
Latin Clinical Trial Center
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Knopp KL, Downing AM, Anthony L, Chaterjee S, Price K, Sparks J. An innovative phase 2 chronic pain master protocol design to assess novel mechanisms in multiple pain types. Pain Rep. 2024 Oct 16;9(6):e1203. doi: 10.1097/PR9.0000000000001203. eCollection 2024 Dec.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H0P-MC-CPMP
Identifier Type: OTHER
Identifier Source: secondary_id
17511
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.